When should denosumab (Prolia) be initiated after discontinuing teriparatide (Forteo)?

When to Start Prolia After Stopping Forteo

Denosumab (Prolia) should be initiated promptly—ideally within 1-3 months—after discontinuing teriparatide (Forteo) to prevent rapid bone loss and maintain the bone density gains achieved during anabolic therapy. 1

Critical Timing Rationale

The Endocrine Society Clinical Practice Guidelines explicitly recommend that after completing teriparatide or abaloparatide, antiresorptive osteoporosis therapies must be started to maintain bone density gains 1. This is not optional—it's a strong recommendation based on the pharmacology of these agents.

Why Timing Matters

When teriparatide is stopped without follow-on therapy, the anabolic effects rapidly dissipate:

• Bone turnover markers return to baseline or higher within months of stopping teriparatide
• Bone mineral density (BMD) gains are lost without antiresorptive consolidation therapy
• Research demonstrates that women who received no follow-up therapy after teriparatide experienced spine BMD decreases of -10.0% within 15 months 2

In contrast, those who received prompt antiresorptive therapy (started within ~4 months) maintained their BMD gains, with spine BMD changes of only -1.2% 2.

Optimal Transition Window

Start denosumab within 1-3 months after the last teriparatide dose. The evidence supporting this includes:

• The DATA-Follow-up study showed that antiresorptive therapy initiated at a mean of 3.8 months after stopping teriparatide successfully maintained BMD 2
• Patients who started follow-on therapy within this timeframe preserved femoral neck, total hip, and spine BMD
• Delays beyond 6 months risk significant bone loss and increased fracture vulnerability

Denosumab-Specific Advantages

Denosumab is particularly effective as follow-on therapy after teriparatide:

• Continued BMD gains: Sequential teriparatide followed by denosumab produces additional increases in BMD at lumbar spine (+5.2% at 12 months, +6.9% at 24 months), total hip (+2.9% and +4.6%), and femoral neck (+3.0% and +4.7%) 3
• Superior to bisphosphonates: Denosumab yields significantly greater lumbar spine BMD gains compared to bisphosphonates after teriparatide (though hip/femoral neck gains are similar) 4
• Rapid onset: Denosumab suppresses bone turnover markers by 75-85% within 3 months 3

Over the entire treatment sequence (24 months teriparatide + 24 months denosumab), cumulative BMD increases reach 21.9% at lumbar spine, 9.8% at total hip, and 9.5% at femoral neck 3.

Critical Pitfalls to Avoid

Do NOT Delay Denosumab Initiation

• Waiting beyond 6 months risks losing all teriparatide-induced gains
• The longer the gap, the more bone loss occurs
• Real-world data shows only 6% of Medicare patients actually receive follow-on therapy within 1 year of stopping denosumab (though this statistic is for denosumab discontinuation, it illustrates poor real-world adherence to transition protocols) 5

Do NOT Switch FROM Denosumab TO Teriparatide

This is the opposite sequence and produces inferior results:

• Switching from denosumab to teriparatide results in BMD loss rather than gains 6
• Cortical porosity increases and bone strength decreases with this transition 6
• This sequence should be avoided 6

Ensure Adequate Calcium and Vitamin D

• Denosumab can cause hypocalcemia, particularly in patients with vitamin D deficiency or chronic kidney disease 1
• Check and correct vitamin D deficiency before starting denosumab
• Ensure adequate calcium supplementation (typically 1000 mg calcium + 800 IU vitamin D daily) 7

Practical Implementation

1. Schedule denosumab injection 1-3 months after last teriparatide dose
2. Check serum calcium and vitamin D levels before first denosumab dose
3. Correct any deficiencies before initiating denosumab
4. Administer denosumab 60 mg subcutaneously every 6 months 1
5. Do not miss or delay subsequent denosumab doses—this medication has no "drug holiday" option due to rebound bone resorption risk 1

Long-Term Considerations

• Denosumab should be continued for 5-10 years with ongoing fracture risk reassessment 1
• Never stop denosumab abruptly without transitioning to another antiresorptive (bisphosphonate) due to severe rebound vertebral fracture risk 1
• The combination of teriparatide followed by denosumab represents one of the most effective sequential strategies for severe osteoporosis 3, 6